CoChat

1160-P: Continuous Glucose Monitoring in Youth-Onset Type 2 Diabetes—Interim Results from Pilot Randomized Controlled 12-Week Trial

PATEL, TEJAL, ESTRADA, DORIS E., MEYERS, ABBY, MACKEY, ELEANOR, CHUNG, STEPHANIE T. · 2024 · Diabetes
Cited by 1

The DOI matches its Crossref record.

Abstract

Introduction: Continuous glucose monitors (CGM) may improve diabetes self-management in youth-onset type 2 diabetes (Y-T2D), but feasibility in Y-T2D on infrequent self-monitoring blood glucose (SMBG) regimens and device burden is unclear. This is an interim analysis of primary aims to assess CGM feasibility (recruitment >60%) and acceptability (wear time >60%) and explore diabetes burden and adverse events. Methods: This is an active 12-week randomized 2:1, two arm parallel pilot trial of CGM vs fingerstick monitoring (Con) in Y-T2D prescribed SMBG <3 times daily (not on multiple insulin injections). Diabetes distress was measured with Diabetes Distress and CGM benefit/burden scale. Results: Between August-December 2023, recruitment rate was 60% [40 screened, 24 enrolled (14 CGM, 10 Con; 77% female, 69% Black, 14.9±3.8y, BMI: 36.2±7.7 kg/m2, HbA1c: 7.3± 2.6% (mean±SD))]. Most cited reasons for declining were reluctance to wear a device (31%) or study participation (25%). 45% (6 CGM, 5 Con) completed the study; one Con was lost to follow-up. Among CGM, wear time was 62% at 1st 6 weeks [n=11], 49% at 2nd 6 weeks [n=6], and 61% at 12 weeks [n=6], P=0.11. Among Con, blood glucoses were reported in 66% at 1st 6 weeks [n=6] and 20% at 12 weeks [n=5]. 75% of CGM users had sensors dislodged. Diabetes distress score did not change: CGM:1.8 ±0.9 to 1.3±0.1 and control: 1.2±0.2 to 1.2±0.1. No difference in mean CGM burden scale; 17±4.8 to ±7.6. Conclusion: CGM use in Y-T2D may be feasible but device-related events were common. There is no increase in disease burden with technology use. Disclosure: T. Patel: None. D.E. Estrada: None. A. Meyers: None. E. Mackey: None. S.T. Chung: None. Funding: Endocrine Fellows Foundation 2023; Dexcom, Inc

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db24-1160-p

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 1

Metadata

Authors
PATEL, T., ESTRADA, D. E., MEYERS, A., MACKEY, E., & CHUNG, S. T.
Affiliations
Washington, DC, Bethesda, MD
Venue
Diabetes
Published
2024-06-14
Volume
73
Issue
Supplement_1
ISSN
0012-1797
Cited by
0
References
0
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 1160-P: Continuous Glucose Monitoring in Youth-Onset Type 2 Diabetes—Interim Results from Pilot Randomized Controlled 12-Week Trial. https://app.cochat.ai/papers/10.2337/db24-1160-p
The paper
PATEL, T., ESTRADA, D. E., MEYERS, A., MACKEY, E., & CHUNG, S. T. (2024). 1160-P: Continuous Glucose Monitoring in Youth-Onset Type 2 Diabetes—Interim Results from Pilot Randomized Controlled 12-Week Trial. Diabetes. https://doi.org/10.2337/db24-1160-p

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.